For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | |
|---|---|---|---|---|
| Total revenue | 0 | -17* | 10 | |
| Research and development | 17.319 | 15* | 19.639 | |
| General and administrative | 6.635 | 9* | 3.689 | |
| Total operating expenses | 23.954 | 24* | 23.328 | |
| Loss from operations | -23.954 | -41* | -13.328 | |
| Change in fair value of convertible preferred stock forward | - | 9* | - | |
| Interest income | 2.284 | 1* | 0.862 | |
| Other expense, net | 0.004 | 0* | 0.009 | |
| Total other income, net | 2.28 | 10* | 0.853 | |
| Net loss | -21.674 | -31 | -12.475 | |
| Basic EPS | -0.64 | -2.931 | -8.07 | |
| Diluted EPS | -0.64 | -2.931 | -8.07 | |
| Basic Average Shares | 33,670,148 | 10,728,262 | 1,545,010 | |
| Diluted Average Shares | 33,670,148 | 10,728,262 | 1,545,010 | |
Evommune, Inc. (EVMN)
Evommune, Inc. (EVMN)